CEO | CIO: Evan A. Rubinson
Evan Rubinson is the founder of Koroit Capital and serves as the Fund’s Chief Executive Officer and Chief Investment Officer. Leveraging his expertise in finance, as well as his knowledge of policymaking and government regulation, has enabled him to successfully navigate the complex waters of the healthcare and biotechnology spaces. Mr. Rubinson maintains an expertise for analyzing myriad critical investment factors, in concert, such as a financials, clinical data, management team, geographical audience, FDA sentiment, investor sentiment, and ultimate feasibility of FDA approval. This all-encompassing investment approach facilitates a unique perspective that enables him to successfully identify companies that possess deep-value, blockbuster drug potential, and a ripeness for acquirement. Prior to founding Koroit Capital, Evan worked as a private equity analyst with Prometheus Partners.
At Prometheus Partners, he created large-scale projection models to predict future cash flows of various investments within the private equity firm’s apparatus. He also built proprietary excel pricing models, as well as multiple linear regression models, in order to precisely determine statistical variables that had previously been estimated. During legislative and regulatory changes, Evan worked closely with the compliance department to ensure the firm’s internal compliance procedures were properly adopted and adhered to, according to new SEC rules and regulations, as well as overseeing the broad-based implementation of all necessary operational and procedural modifications.
Mr. Rubinson holds a B.A. from Duke University, having majored in Economics and Public Policy. In June of 2012, he became certified by Training the Street (TTS), for Financial Modeling, Financial Statement Analysis and Accounting, M&A Consequence Analysis, LBO analysis, Corporate Valuation, and Public and Acquisition Comparables.
Evan currently serves as the Founder, CEO and CIO of Koroit Capital; the Founder and CEO of ERA Music Brands; the CEO and President of Meters Music; the co-owner of Dean Guitars, Luna Guitars and ddrum Percussion; the Majority Shareholder of Kapok Pavilion; and a Director of EPR Investments.
CSO: Garrett T. Ruhland
Garrett T. Ruhland is the Chief Scientific Officer of Koroit Capital. Prior to joining Koroit Capital, Mr. Ruhland honed his expertise in biotechnology, healthcare, digital health and software development, through such endeavors as serving as head of R&D for truBrain and CEO for Modern AlkaMe Inc. He is particularly well versed in the areas of developing scientific-based growth strategies, analysis of clinical data, and assessment of the FDA approval processes.
As head of R&D at truBrain, a brain-health nutraceutical company, Mr. Ruhland patented and developed their flagship product, grew new product revenues, upgraded manufacturing plants to FDA standards, and redirected an underperforming product line by adapting a new business model to capture the shift in consumer demand while validating product efficacy through double-blind clinical trials. As CEO of Modern AlkaMe Inc., he developed one of the first consumer facing digital health platforms aimed at quantifying user-diet through the development of a machine-learning digital phenotype that aggregates user health data sourced from electronic health records, blood panels, genotypes and wearable devices in order to measure the impact diet and medications would have on a consumer; creating one of the first biometric driven commerce companies.
Mr. Ruhland is an expert in translating medical and clinical research into commercially viable solutions. His greatest strength lies in his ability to fluently communicate between Medical, Software, Legal & Management teams to facilitate optimal collaboration and project execution. His unique experience as a product CEO gives him the ability to shrewdly ascertain the commercial viability of not only a company’s product or service but also a team’s ability to bring it to market. Mr. Ruhland has a Bachelor of Science in Neurochemistry & Molecular Biology from Duke University.
Expert Advisor: Dolo Nosamiefan
Dolo attend Harvard University, majoring in biomedical and medical engineering. During his time at university, he conducted research at the Harvard Broad Institute, eventually gaining publication in key medical journals.
Koroit Capital 